Sobi to host a Capital Markets Day on 18 February 2026
Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will…
38,480€
-1,28%
Echtzeit-Aktienkurs Swedish Orphan Biovitrum AB
Bid:
Ask:
Nachrichten zur Swedish Orphan Biovitrum AB Aktie
Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
Swedish Orphan Biovitrum AB (publ) Sobi® (STO:SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of…
Sobis 2025 annual revenue and adjusted EBITA margin exceed previous outlook
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was approximately SEK 28.2 B, representing approximately 15 per cent growth at constant exchange rate (CER)[1]. Adjusted EBITA margin1,[2] was approximately 40 per cent…
Swedish Orphan Biovitrum AB (publ) (SWOBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
…
Swedish Orphan Biovitrum AB (publ) (SWOBY) M&A Call Transcript
…
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q3 2025 Earnings Call Transcript
…
Sobi setzt auf Kinaxis, um den Zugang zu lebensverändernden Behandlungen zu beschleunigen
OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® (TSX:KXS), ein Weltmarktführer im Bereich der End-to-End-Lieferkettenkoordination, gab heute bekannt, dass Swedish Orphan Biovitrum AB (Sobi), ein…
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2025 Earnings Call Transcript
…
Swedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’
Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the pharmaceutical industry…
Sobis full year 2024 revenue higher than previous estimate
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous…
Bulletin from Sobi’s Extraordinary General Meeting (EGM)
The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee’s proposals,…
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting…
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript
…
New number of shares and votes in Sobi
As per 30 September 2024, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 356,000,049…
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript
…
BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®
Bergen, Norway, May 28, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors…
Sobi has completed SEK 3 billion senior bond issue
Swedish Orphan Biovitrum AB (publ) (Sobi[®]) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under…
Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
Swedish Orphan Biovitrum AB (publ) (Sobi[®]) has established a medium term note programme with a framework amount of SEK 10…
Swedish Orphan Biovitrum AB (publ) 2024 Q1 - Results - Earnings Call Presentation
…
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
First Quarter 2024
• Total revenue increased…